Bayer’s Finerenone Shows Renal, CV Benefits In CKD/Type 2 Diabetes Patients – But Is It Enough?

 
• By Joseph Haas
Kidney
Bayer plans to file finerenone for reduction of renal, CV outcomes risk

More from Clinical Trials

More from R&D